Latest revenue
$15.00B
as of 2026-03-31
Latest net income
$695.0M
as of 2026-03-31
Net margin
4.6%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $381.10B
- Enterprise value
- $444.21B
- P/E (trailing)
- 90.2×
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 3.1%
- 52-wk high
- $244.81
- 52-wk low
- $181.73
- Beta
- —
- Shares out
- 1.77B
5-year trend
What this company does
AbbVie is a global biopharmaceutical company that develops and sells prescription drugs across immunology, oncology, neuroscience, aesthetics, and eye care, with key products including Skyrizi, Rinvoq, and Botox. It generates revenue almost entirely from branded drug sales, booking $15.0 billion in Q1 2026, up 12% year-over-year. The company is navigating life after Humira's loss of exclusivity by leaning on Skyrizi/Rinvoq growth and bolt-on deals like Nimble Therapeutics, while carrying a stockholders' deficit and roughly $73 billion in debt.
Key risks
- Stockholders' deficit widened to $(6.6)B from $(3.3)B as dividends ($3.07B) and buybacks ($1.49B) again exceeded Q1 net earnings of $695M.
- Leverage rising: long-term debt jumped to $64.5B from $58.9B after $8B new issuance; Q1 interest expense $717M against shrinking earnings.
- Contingent consideration remeasurement drove $2.39B non-cash charge, cutting EPS to $0.39 from $0.72; ongoing ImmunoGen/Cerevel earn-out volatility risk.
Profitability
Operating margin
24.6%
52.0%Net margin
6.9%
9.0%Return on equity
-129.2%
200.4%Return on assets
3.2%
0.3%Leverage
Debt / equity
-41.97×
205.8%Long-term debt / equity
-18.02×
199.3%Debt / assets
102.4%
5.0%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $15.00B | +12.4% | $695.0M | -46.0% | 4.6% |
Q4 2025 2025-12-31 | $16.62B | +10.0% | $1.82B | +8354.5% | 10.9% |
Q3 2025 2025-09-30 | $15.78B | +9.1% | $186.0M | -88.1% | 1.2% |
Q2 2025 2025-06-30 | $15.42B | +6.6% | $938.0M | -31.5% | 6.1% |
Q1 2025 2025-03-31 | $13.34B | +8.4% | $1.29B | -6.1% | 9.6% |
Q4 2024 2024-12-31 | $15.10B | — | $-22.0M | — | -0.1% |
Q3 2024 2024-09-30 | $14.46B | +3.8% | $1.56B | -12.2% | 10.8% |
Q2 2024 2024-06-30 | $14.46B | +4.3% | $1.37B | -32.3% | 9.5% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on ABBV — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$21.8M
Net activity
−$21.8M
Distinct insiders
4
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ABBV
Institutional value
$71.05B
Total shares held
335.3M
Distinct holders
740
As of
2026-03-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 114.9M | $24.99B | — | New |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 49.5M | $10.77B | — | New |
| 3 | Legal & General Group Plc | 12.2M | $2.64B | — | New |
| 4 | VANGUARD FIDUCIARY TRUST CO | 10.2M | $2.22B | — | New |
| 5 | DEUTSCHE BANK AG\ | 9.5M | $2.07B | — | New |
| 6 | WELLS FARGO & COMPANY/MN | 8.9M | $1.94B | — | New |
| 7 | Invesco Ltd. | 7.8M | $1.70B | — | New |
| 8 | DIMENSIONAL FUND ADVISORS LP | 7.4M | $1.61B | — | New |
| 9 | Swiss National Bank | 5.2M | $1.13B | — | New |
| 10 | Mitsubishi UFJ Asset Management Co., Ltd. | 4.0M | $876.7M | — | New |
| 11 | FEDERATED HERMES, INC. | 4.0M | $865.6M | — | New |
| 12 | National Pension Service | 3.9M | $859.0M | — | New |
| 13 | TD ASSET MANAGEMENT INC | 3.9M | $852.6M | — | New |
| 14 | Vanguard Global Advisers, LLC | 3.9M | $849.4M | — | New |
| 15 | STIFEL FINANCIAL CORP | 3.7M | $811.7M | — | New |
| 16 | California Public Employees Retirement System | 3.7M | $809.1M | — | New |
| 17 | VANGUARD ASSET MANAGEMENT, Ltd | 3.6M | $774.2M | — | New |
| 18 | Boston Partners | 3.4M | $746.1M | — | New |
| 19 | PNC Financial Services Group, Inc. | 3.4M | $739.9M | — | New |
| 20 | BNP PARIBAS FINANCIAL MARKETS | 3.0M | $662.0M | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
- 1
Q1 net earnings fell 46% to $695M despite 12% revenue growth—how much of the $2.3B 'other expense' is recurring contingent consideration revaluation versus one-time?
- 2
Stockholders' deficit widened to $(6.6)B with dividends of $3.1B exceeding net income—at what leverage threshold do you reconsider the buyback or dividend trajectory?
- 3
Long-term debt rose $5.6B to $64.5B this quarter; what acquisitions or Humira erosion gaps is this $8B debt raise actually funding?